Vivani Medical
VANI on Nasdaq. Market value $91m.
Should I look at this?
Look carefully before going further
Why it could be worth it
Nothing stands out yet.
What to watch out for
Read the warning sign in its own filings
This is not advice.
Who owns it
None of the long-term investors we follow own it. 38 funds in all.
Largest holders overall
- Vanguard Capital Management$2mAdded
- Tanager Wealth Management LLP$753,022Cut
- Geode Capital Management$728,911Cut
- Tudor Investment Corp ET AL$509,518Cut
- Commonwealth Equity Services$409,900
- Vanguard Fiduciary Trust$403,573Added
- BlackRock$374,267
- Monetary Management Group$240,531
- State Street$192,157
- Northern Trust$144,965Added
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
1 investor owns more than 5%.
- Williams GreggInsider or founderat least 47.1%(filed with 4 related holders)Since 15 May 2026
What they said
The Reporting Persons, directly or indirectly through certain affiliates, acquired the shares of the Issuer for investment purposes. Nevertheless, as a result of his appointment in March 2018 as the non-executive Chairman of the Board of Directors and his beneficial share…
Read the filing
| Holder | Stake | Since | |
|---|---|---|---|
Williams Gregg Insider or founder | at least 47.1% (filed with 4 related holders) | 15 May 2026 | What they saidThe Reporting Persons, directly or indirectly through certain affiliates, acquired the shares of the Issuer for investment purposes. Nevertheless, as a result of his appointment in March 2018 as the non-executive Chairman of the Board of Directors and his beneficial share… Read the filing |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
In the last 12 months, 3 insiders bought $17m of shares on the open market.
- Williams GreggDirectorBought
- Date
- 19 November 2026
- Shares
- 85,265
- Price
- $1.09
- Value
- $93,365
- Williams GreggDirectorBought
- Date
- 18 November 2026
- Shares
- 33,169
- Price
- $1.05
- Value
- $34,960
- Williams GreggDirectorBought
- Date
- 17 November 2026
- Shares
- 29,929
- Price
- $1.05
- Value
- $31,455
- Williams GreggDirectorBought
- Date
- 16 November 2026
- Shares
- 2,100
- Price
- $1.01
- Value
- $2,121
- Williams GreggDirectorBought
- Date
- 13 November 2026
- Shares
- 48,100
- Price
- $0.99
- Value
- $47,763
- Dwyer DonaldChief Business OfficerBought
- Date
- 12 November 2026
- Shares
- 20,000
- Price
- $0.98
- Value
- $19,645
- Williams GreggDirectorBought
- Date
- 15 July 2026
- Shares
- 793,650
- Price
- $1.26
- Value
- $999,999
- Williams GreggDirectorBought
- Date
- 15 June 2026
- Shares
- 1,587,301
- Price
- $1.26
- Value
- $2m
- Williams GreggDirectorBought
- Date
- 15 May 2026
- Shares
- 1,587,301
- Price
- $1.26
- Value
- $2m
- Williams GreggDirectorBought
- Date
- 15 April 2026
- Shares
- 1,587,301
- Price
- $1.26
- Value
- $2m
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 19 November 2026 | Williams Gregg Director | Bought | 85,265 | $1.09 | $93,365 |
| 18 November 2026 | Williams Gregg Director | Bought | 33,169 | $1.05 | $34,960 |
| 17 November 2026 | Williams Gregg Director | Bought | 29,929 | $1.05 | $31,455 |
| 16 November 2026 | Williams Gregg Director | Bought | 2,100 | $1.01 | $2,121 |
| 13 November 2026 | Williams Gregg Director | Bought | 48,100 | $0.99 | $47,763 |
| 12 November 2026 | Dwyer Donald Chief Business Officer | Bought | 20,000 | $0.98 | $19,645 |
| 15 July 2026 | Williams Gregg Director | Bought | 793,650 | $1.26 | $999,999 |
| 15 June 2026 | Williams Gregg Director | Bought | 1,587,301 | $1.26 | $2m |
| 15 May 2026 | Williams Gregg Director | Bought | 1,587,301 | $1.26 | $2m |
| 15 April 2026 | Williams Gregg Director | Bought | 1,587,301 | $1.26 | $2m |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
1 serious warning sign in Vivani Medical’s filings.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 26 Mar 2026, plus the 10-Q filed 12 Nov 2026 and 13 later 8-Ks.
Doubt it can keep going
SeriousThe company or its auditor warned it may not have enough money to last the next year.
“These conditions raise substantial doubt about our ability to continue as a going concern within one year after the date these condensed consolidated financial statements are issued.”
Show the full paragraph
Our condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We have experienced recurring operating losses and negative operating cash flows since inception and we expect to continue to incur operating losses and negative operating cash flows for the foreseeable future. To date, we have financed our working capital requirements through the recurring sale of our equity securities. We estimate that currently available cash will provide sufficient funds to enable us to meet our planned obligations through the first quarter of 2027. Our ability to operate as planned beyond such date is dependent on our ability to raise additional capital, however, there can be no assurances that we will be able to do so. These conditions raise substantial doubt about our ability to continue as a going concern within one year after the date these condensed consolidated financial statements are issued.
From the 10-Q filed 12 November 2026, Part I, Item 2. Management's Discussion and Analysis. Read it in the filing
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
A serious warning sign just appeared in its filings. Read what it says before you buy.
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.